脑再生科技（RGC）股价在夜盘交易中再度下跌5.06%，延续了近日的大幅回调趋势。这家专注于开发中医治疗方案的生物科技公司，近期股价表现极为波动，引发市场广泛关注。
据悉，脑再生科技此前两个交易日曾累计上涨近400%，股价一度飙升至83.6美元的历史新高。然而，上周五该股突然大跌40%，周一盘中又下跌超过30%，夜盘继续下跌，显示出强烈的回调态势。该公司主要业务是开发三种液态标准化中药配方，用于治疗不同程度的注意缺陷多动障碍（ADHD）和自闭症谱系障碍（ASD）患者。
分析人士指出，脑再生科技股价的剧烈波动反映了投资者情绪的快速变化。在经历了近期的暴涨之后，部分投资者可能选择获利了结，导致股价承压。此外，考虑到公司作为早期生物科技企业的特性，一些投资者可能对其估值产生疑虑，进而引发持续抛售。目前，市场将密切关注该公司的基本面发展和后续公告，以评估其长期投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.